Description
GM-CSF Monoclonal Antibody
| Catalog number: | B2015332 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 10 g |
| Molecular Weight or Concentration: | N/A |
| Supplied as: | Solution |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | GM-CSF Monoclonal antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Childrens Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma N Engl J Med. 2010 Sep 30;363(14):1324-34.
- Mody R, Yu AL, Naranjo A, Zhang FF, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Hank JA, Felder M, Birstler J, Sondel PM, Asgharzadeh S, Glade-Bender J, Katzenstein H, Maris JM, Park JR, Bagatell R. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Childrens Oncology Group J Clin Oncol. 2020 Jul 1;38(19):2160-2169.
- Nair JR, Edwards SW, Moots RJ. Mavrilimumab, a human monoclonal GM-CSF receptor- antibody for the management of rheumatoid arthritis: a novel approach to therapy Expert Opin Biol Ther. 2012 Dec;12(12):1661-8.
- Patel J, Bass D, Beishuizen A, Bocca Ruiz X, Boughanmi H, Cahn A, Colombo H, Criner GJ, Davy K, de-Miguel-Dez J, Doreski PA, Fernandes S, Franois B, Gupta A, Hanrott K, Hatlen T, Inman D, Isaacs JD, Jarvis E, Kostina N, Kropotina T, Lacherade JC, Lakshminarayanan D, Martinez-Ayala P, McEvoy C, Meziani F, Monchi M, Mukherjee S, Muoz-Bermdez R, Neisen J, OShea C, Plantefeve G, Schifano L, Schwab LE, Shahid Z, Shirano M, Smith JE, Sprinz E, Summers C, Terzi N, Tidswell MA, Trefilova Y, Williamson R, Wyncoll D, Layton M. A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR) Eur Respir J. 2023 Feb 2;61(2):2101870.
- Corbera-Bellalta M, Alba-Rovira R, Muralidharan S, Espgol-Frigol G, Ros-Garcs R, Marco-Hernndez J, Denuc A, Kamberovic F, Prez-Galn P, Joseph A, DAndrea A, Bondensgaard K, Cid MC, Paolini JF. Blocking GM-CSF receptor with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis Ann Rheum Dis. 2022 Apr;81(4):524-536.
- Avci AB, Feist E, Burmester GR. Targeting GM-CSF in rheumatoid arthritis Clin Exp Rheumatol. 2016 Jul-Aug;34(4 Suppl 98):39-44. Epub 2016 Jul 21.
- Kushner BH, Cheung NK. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma Blood. 1989 May 15;73(7):1936-41.
- Bonaventura A, Vecchi A, Wang TS, Lee E, Cremer PC, Carey B, Rajendram P, Hudock KM, Korbee L, Van Tassell BW, Dagna L, Abbate A. Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies Front Immunol. 2020 Jul 3;11:1625.
- Hingorani P, Krailo M, Buxton A, Hutson P, Sondel PM, Diccianni M, Yu A, Morris CD, Womer RB, Crompton B, Randall RL, Teot LA, DuBois SG, Janeway KA, Gorlick RG, Isakoff MS. Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Childrens Oncology Group Eur J Cancer. 2022 Sep;172:264-275.
